Omeros Corporation (NASDAQ:OMER) today announced the upcoming presentation of a report detailing narsoplimab treatment in nine adult patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Narsoplimab is Omeros' investigational antibody targeting MASP-2, the effector enzyme of the lectin pathway of the complement system.
The report was authored by an external group of U.S. investigators involved in the treatment of these patients with narsoplimab provided under Omeros' compassionate use program. It will be featured as a poster presentation at the 2024 Tandem Meetings – the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research, to be held February 21-24, 2024 in San Antonio, Texas.
The poster will be presented by Lindsay Adkins, MSN, FNP-BC, BMTCN, of the Sarah Cannon Transplant and Cellular Therapy Program, Nashville, Tennessee. Details of the presentation are as follows:
Real-World Experience with Narsoplimab (OMS721) for the Treatment of Transplant-Associated Thrombotic Microangiopathy (Poster #186)
Poster Session: Acute Regimen-Related Toxicity and Supportive Care
Date: Thursday, February 22, 2024
Presentation Time: 6:45 - 7:45 p.m. CST
Location: Exhibit Hall 4A
The presentation abstract is available now on the Tandem Meetings website at the following link:
The poster is expected to be made available on Omeros' website at shortly after the meeting presentation.